Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Name: Kaimen Rigor review — Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Item: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Rating: 100
Author: Alpha1

Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 0 high issues for “Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03738-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b0a3cd17-5f4e-46d7-a111-94dc0d395c2c" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b0a3cd17-5f4e-46d7-a111-94dc0d395c2c/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 0 high issues for “Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0c3e4cdf95462560393d6ff8c16cdc8226cbbbd538be8acf06ca2c302547d2a0

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Paper source

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 2 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is event-free survival (EFS), a composite of recurrence of high-grade disease, progression, persistence of CIS, or death. EFS is a surrogate for long-term clinical outcomes such as overall survival or progression to muscle-invasive disease. The paper does not provide evidence linking EFS to a validated clinical outcome in this setting, nor does it demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) for sasanlimab. The OS interim analysis showed no difference between arms, and the BICR sensitivity analysis for EFS was not statistically significant.
“The primary endpoint was investigator-assessed event-free survival (EFS) for Arm A versus Arm C; ... The trial met its primary endpoint with a statistically significant and clinically meaningful prolongation of EFS (Arm A versus Arm C); hazard ratio, 0.68…”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a hazard ratio of 0.68 for EFS, with 36-month EFS rates of 82.1% vs 74.8% (absolute difference 7.3%). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a validated threshold for EFS in NMIBC. The OS interim analysis showed no difference (HR 1.13), and the BICR sensitivity analysis was not significant (HR 0.75, P=0.0517), raising uncertainty about the robustness of the effect.
“The risk of experiencing an EFS event was 32% lower in Arm A versus Arm C (stratified hazard ratio (HR), 0.68 (95% confidence interval (CI): 0.49–0.94); one-sided P = 0.0095) ... The probability of being event free at 36 months was 82.1% for Arm A and 74.8%…”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized trial. The paper demonstrates strong methodological rigor in design, statistical analysis, and reporting, with minor gaps in explicit discussion of prior limitations and outlier handling.

Both reviewers classified the study as interventional and agreed on all dimensions. Minor divergences on outlier handling and reporting guideline were resolved by weighing the specific evidence; the paper's overall status remains pass. Statistics verification covered only a subset of tests (5 checked, all consistent); other statistics remain unverified.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior research on BCG as standard of care, the unmet need, and the rationale for combining PD-1 inhibition with BCG based on preclinical and clinical evidence. The hypothesis follows logically from the cited evidence. Limitations of prior research are implicitly addressed by the design of a phase 3 trial, though not explicitly discussed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

“Clinical trials have examined the efficacy and safety of PD-(L)1 inhibitors in BCG-naive and post-BCG NMIBC settings”

Introduction ¶1Find in source

“Exposure to BCG is associated with increased PD-L1 expression in preclinical models and tumors from patients with high-risk NMIBC”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

“Clinical trials have examined the efficacy and safety of PD-(L)1 inhibitors in BCG-naive and post-BCG NMIBC settings”

Introduction ¶1Find in source

“Exposure to BCG is associated with increased PD-L1 expression in preclinical models and tumors from patients with high-risk NMIBC”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed in the introduction.

Randomization method is described (1:1:1) with stratification by CIS and geographic region. The unit of randomization is the patient. Blinding is not applicable as the trial is open-label, but the paper provides a rationale and mitigation via BICR. Power analysis is reported with assumptions and sample size. Inclusion/exclusion criteria are described. Outlier handling is not explicitly addressed, but the analysis population (ITT) and safety set are defined. Controls are inherent in the comparator arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with adequate randomization, stratification, and pre-specified analysis, though blinding is not applicable due to open-label design.

Evidence

“Patients were randomized 1:1:1 to receive sasanlimab in combination with BCG induction and maintenance (BCG-I+M; Arm A), sasanlimab with BCG induction only (BCG-I; Arm B) or BCG-I+M (Arm C). Randomization was stratified by the presence of CIS (yes or no) and geographic region”

MethodsFind in source

“Under the assumptions of an HR of 0.69 and a median EFS of 24 months in Arm C, 389 EFS events would be required for each comparison to provide 90% power”

Statistical analysisFind in source

“One limitation of the trial was the open-label design, which was mitigated by the retrospective BICR of tumor biopsy and imaging”

Discussion ¶8Find in source

PASSReviewer 2· 90% conf

The trial design is rigorous with adequate randomization, stratification, and statistical planning, though blinding is not applicable due to open-label design.

Evidence

MethodsFind in source

“Under the assumptions of an HR of 0.69 and a median EFS of 24 months in Arm C, 389 EFS events would be required for each comparison to provide 90% power”

Statistical analysisFind in source

“One limitation of the trial was the open-label design, which was mitigated by the retrospective BICR of tumor biopsy and imaging”

Discussion ¶8Find in source

Sex is reported (81.8% male). Age is reported (median 67 years). Demographics include race and ethnicity. Disease characteristics such as T stage and CIS presence are reported. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline disease characteristics are well reported, including sex, age, race, and disease stage.

Evidence

“The median age was 67 years (range, 31–91); 81.8% of patients were men”

ResultsFind in source

“61.2% of patients were White, 35.5% were Asian and 0.9% were Black or African American”

ResultsFind in source

“54.2% had T1 tumor as the highest grade; and 25.5% had CIS with or without papillary tumors”

ResultsFind in source

PASSReviewer 2· 90% conf

Demographic and baseline disease characteristics are well reported, including sex, age, race, and disease stage.

Evidence

“The median age was 67 years (range, 31–91); 81.8% of patients were men”

ResultsFind in source

“61.2% of patients were White, 35.5% were Asian and 0.9% were Black or African American”

ResultsFind in source

The paper states approval by institutional review boards/ethics committees at each site, compliance with the Declaration of Helsinki and GCP, and written informed consent from patients. The protocol was also approved by HGRAC in China. Regulatory compliance is explicitly stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and informed consent are adequately reported.

Evidence

“it was approved by the institutional review board or ethics committee at each site”

MethodsFind in source

“Patients provided written informed consent before trial entry.”

MethodsFind in source

“conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines and applicable regulatory requirements”

MethodsFind in source

PASSReviewer 2· 90% conf

Ethical approvals and informed consent are adequately reported.

Evidence

paraphrase[Methods, Inclusion and ethics]

“it was approved by the institutional review board or ethics committee at each site and was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines and applicable regulatory requirements. Patients provided written informed consent before trial entry.”

Sasanlimab is identified as a humanized anti-PD-1 antibody, and BCG is named. The PD-L1 assay (VENTANA SP263) is specified. Software used for analysis (SAS 9.4) is identified. No cell lines, antibodies, or organisms are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (sasanlimab) and BCG are adequately identified, and the PD-L1 assay is specified.

Evidence

“Sasanlimab is a humanized, monoclonal antibody specific for human PD-1”

Introduction ¶3Find in source

“PD-L1 status was assessed by the VENTANA PD-L1 immunohistochemistry SP263 assay”

MethodsFind in source

“Analyses were performed using SAS version 9.4 software.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (sasanlimab) and BCG are adequately identified, and the PD-L1 assay is specified.

Evidence

“Subcutaneous sasanlimab (300 mg) was administered in a 2-ml prefilled syringe on day 1 of each 4-week cycle, for up to 25 cycles. Intravesical BCG induction occurred as one dose weekly via instillation for six consecutive weeks”

MethodsFind in source

“PD-L1 status was assessed by the VENTANA PD-L1 immunohistochemistry SP263 assay”

MethodsFind in source

“Analyses were performed using SAS version 9.4 software.”

Statistical analysisFind in source

Statistical tests are named (stratified log-rank test, Cox proportional hazards model, Mantel-Haenszel test). Assumptions are handled by design (stratified Cox model). Exact p-values are reported (e.g., P = 0.0095). Effect sizes with 95% CIs are reported. Software is identified. Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility checks were not performed due to large N and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“Comparisons between Arms A and B versus Arm C were conducted using the stratified log-rank test.”

Statistical analysisFind in source

“one-sided P = 0.0095”

ResultsFind in source

“stratified hazard ratio (HR), 0.68 (95% confidence interval (CI): 0.49–0.94)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with exact p-values and effect sizes with confidence intervals.

Evidence

“Comparisons between Arms A and B versus Arm C were conducted using the stratified log-rank test.”

Statistical analysisFind in source

“one-sided P = 0.0095”

ResultsFind in source

“stratified hazard ratio (HR), 0.68 (95% confidence interval (CI): 0.49–0.94)”

ResultsFind in source

The data availability statement provides a concrete mechanism for requesting deidentified participant data via a secure portal, with conditions and timeframe. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access route via Pfizer's data-sharing portal.

Evidence

“Upon reasonable request and subject to review, Pfizer will provide the data that support the findings of this trial.”

Data availabilityFind in source

“The deidentified participant data will be made available to researchers whose proposals meet the research criteria and other conditions and, for which an exception does not apply, via a secure portal.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access mechanism via Pfizer's data-sharing portal.

Evidence

“Data may be requested from Pfizer trials 24 months after trial completion. The deidentified participant data will be made available to researchers whose proposals meet the research criteria and other conditions and, for which an exception does not apply, via a secure portal.”

Data availabilityFind in source

The trial is registered (NCT04165317). Methods are detailed enough for replication. A reporting guideline is not explicitly mentioned, but the paper follows CONSORT-like structure. All pre-specified outcomes are reported, including negative results (Arm B vs C). Limitations are discussed. Conclusions are proportional to evidence. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT04165317”

AbstractFind in source

“One limitation of the trial was the open-label design”

Discussion ¶8Find in source

“The CREST trial was funded by Pfizer.”

Competing interestsFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT04165317”

AbstractFind in source

“One limitation of the trial was the open-label design”

Discussion ¶8Find in source

“The CREST trial was funded by Pfizer.”

Competing interestsFind in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 2 verified — 23 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the open-label design (mitigated by BICR) and the non-significant BICR sensitivity analysis (P=0.0517) when interpreting the primary endpoint. No erratum is warranted based on this audit.

1.
MEDIUMreporting
In the Introduction, add a sentence explicitly discussing limitations of prior studies (e.g., small sample sizes, lack of randomized data) to strengthen the scientific premise.
Both reviewers flagged that limitations of prior research are not explicitly addressed, which is a minor reporting gap.
2.
MEDIUMreporting
In the Methods, clarify how outliers and missing data (especially for PROs and secondary endpoints) were handled beyond defining ITT and safety populations.
Reviewer 1 rated outlier handling as inadequate; explicit description would improve methodological transparency.
3.
MEDIUMreporting
In the Methods, add a statement about the absence of blinding as a limitation, even though it is discussed in the Discussion.
Reviewer 2 suggested this to improve completeness of the Methods section.
4.
MEDIUMreporting
In the Methods, provide more detail on the randomization implementation (e.g., central randomization system).
Reviewer 2 noted that the randomization method is described but implementation details are sparse.
5.
MEDIUMreporting
In the Results, report the number of patients with PD-L1 unknown status in the baseline table, not just percentages.
Reviewer 2 suggested this to improve clarity of the baseline characteristics.
6.
MEDIUMreporting
In the Discussion, add a statement about the generalizability of the results to other populations (e.g., non-White, female).
Reviewer 2 suggested this to address potential limitations in external validity.
7.
MEDIUMdata code
Provide the full protocol and statistical analysis plan as supplementary material, with a direct link.
Reviewer 2 noted that the protocol is mentioned but not linked; making it accessible would enhance transparency.
8.
LOWcopyedit
In the Abstract, add 'the' before 'standard of care' for grammatical correctness.
Copyedit flagged a minor grammatical issue.
9.
LOWcopyedit
In the Results, ensure consistent use of semicolons and commas in lists (e.g., demographic data).
Copyedit flagged a punctuation inconsistency.
10.
LOWcopyedit
In the Abstract, change 'one-sided P = 0.0095' to 'P = 0.0095 (one-sided)' for consistency with other p-value reporting.
Copyedit flagged a style inconsistency.
11.
LOWcopyedit
In the Results, add 'respectively' after the list of TRAE percentages for clarity.
Copyedit flagged a clarity issue.

Full text (55,664 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03738-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b0a3cd17-5f4e-46d7-a111-94dc0d395c2c" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b0a3cd17-5f4e-46d7-a111-94dc0d395c2c/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 0 high issues for “Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0c3e4cdf95462560393d6ff8c16cdc8226cbbbd538be8acf06ca2c302547d2a0

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 2 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is event-free survival (EFS), a composite of recurrence of high-grade disease, progression, persistence of CIS, or death. EFS is a surrogate for long-term clinical outcomes such as overall survival or progression to muscle-invasive disease. The paper does not provide evidence linking EFS to a validated clinical outcome in this setting, nor does it demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) for sasanlimab. The OS interim analysis showed no difference between arms, and the BICR sensitivity analysis for EFS was not statistically significant.
“The primary endpoint was investigator-assessed event-free survival (EFS) for Arm A versus Arm C; ... The trial met its primary endpoint with a statistically significant and clinically meaningful prolongation of EFS (Arm A versus Arm C); hazard ratio, 0.68…”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a hazard ratio of 0.68 for EFS, with 36-month EFS rates of 82.1% vs 74.8% (absolute difference 7.3%). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a validated threshold for EFS in NMIBC. The OS interim analysis showed no difference (HR 1.13), and the BICR sensitivity analysis was not significant (HR 0.75, P=0.0517), raising uncertainty about the robustness of the effect.
“The risk of experiencing an EFS event was 32% lower in Arm A versus Arm C (stratified hazard ratio (HR), 0.68 (95% confidence interval (CI): 0.49–0.94); one-sided P = 0.0095) ... The probability of being event free at 36 months was 82.1% for Arm A and 74.8%…”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

“Clinical trials have examined the efficacy and safety of PD-(L)1 inhibitors in BCG-naive and post-BCG NMIBC settings”

Introduction ¶1Find in source

“Exposure to BCG is associated with increased PD-L1 expression in preclinical models and tumors from patients with high-risk NMIBC”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

“Clinical trials have examined the efficacy and safety of PD-(L)1 inhibitors in BCG-naive and post-BCG NMIBC settings”

Introduction ¶1Find in source

“Exposure to BCG is associated with increased PD-L1 expression in preclinical models and tumors from patients with high-risk NMIBC”

Introduction ¶3Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed in the introduction.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with adequate randomization, stratification, and pre-specified analysis, though blinding is not applicable due to open-label design.

Evidence

MethodsFind in source

“Under the assumptions of an HR of 0.69 and a median EFS of 24 months in Arm C, 389 EFS events would be required for each comparison to provide 90% power”

Statistical analysisFind in source

“One limitation of the trial was the open-label design, which was mitigated by the retrospective BICR of tumor biopsy and imaging”

Discussion ¶8Find in source

PASSReviewer 2· 90% conf

The trial design is rigorous with adequate randomization, stratification, and statistical planning, though blinding is not applicable due to open-label design.

Evidence

MethodsFind in source

“Under the assumptions of an HR of 0.69 and a median EFS of 24 months in Arm C, 389 EFS events would be required for each comparison to provide 90% power”

Statistical analysisFind in source

“One limitation of the trial was the open-label design, which was mitigated by the retrospective BICR of tumor biopsy and imaging”

Discussion ¶8Find in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline disease characteristics are well reported, including sex, age, race, and disease stage.

Evidence

“The median age was 67 years (range, 31–91); 81.8% of patients were men”

ResultsFind in source

“61.2% of patients were White, 35.5% were Asian and 0.9% were Black or African American”

ResultsFind in source

“54.2% had T1 tumor as the highest grade; and 25.5% had CIS with or without papillary tumors”

ResultsFind in source

PASSReviewer 2· 90% conf

Demographic and baseline disease characteristics are well reported, including sex, age, race, and disease stage.

Evidence

“The median age was 67 years (range, 31–91); 81.8% of patients were men”

ResultsFind in source

“61.2% of patients were White, 35.5% were Asian and 0.9% were Black or African American”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and informed consent are adequately reported.

Evidence

“it was approved by the institutional review board or ethics committee at each site”

MethodsFind in source

“Patients provided written informed consent before trial entry.”

MethodsFind in source

“conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines and applicable regulatory requirements”

MethodsFind in source

PASSReviewer 2· 90% conf

Ethical approvals and informed consent are adequately reported.

Evidence

paraphrase[Methods, Inclusion and ethics]

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (sasanlimab) and BCG are adequately identified, and the PD-L1 assay is specified.

Evidence

“Sasanlimab is a humanized, monoclonal antibody specific for human PD-1”

Introduction ¶3Find in source

“PD-L1 status was assessed by the VENTANA PD-L1 immunohistochemistry SP263 assay”

MethodsFind in source

“Analyses were performed using SAS version 9.4 software.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (sasanlimab) and BCG are adequately identified, and the PD-L1 assay is specified.

Evidence

MethodsFind in source

“PD-L1 status was assessed by the VENTANA PD-L1 immunohistochemistry SP263 assay”

MethodsFind in source

“Analyses were performed using SAS version 9.4 software.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“Comparisons between Arms A and B versus Arm C were conducted using the stratified log-rank test.”

Statistical analysisFind in source

“one-sided P = 0.0095”

ResultsFind in source

“stratified hazard ratio (HR), 0.68 (95% confidence interval (CI): 0.49–0.94)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with exact p-values and effect sizes with confidence intervals.

Evidence

“Comparisons between Arms A and B versus Arm C were conducted using the stratified log-rank test.”

Statistical analysisFind in source

“one-sided P = 0.0095”

ResultsFind in source

“stratified hazard ratio (HR), 0.68 (95% confidence interval (CI): 0.49–0.94)”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access route via Pfizer's data-sharing portal.

Evidence

“Upon reasonable request and subject to review, Pfizer will provide the data that support the findings of this trial.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access mechanism via Pfizer's data-sharing portal.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT04165317”

AbstractFind in source

“One limitation of the trial was the open-label design”

Discussion ¶8Find in source

“The CREST trial was funded by Pfizer.”

Competing interestsFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT04165317”

AbstractFind in source

“One limitation of the trial was the open-label design”

Discussion ¶8Find in source

“The CREST trial was funded by Pfizer.”

Competing interestsFind in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 2 verified — 23 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
MEDIUMreporting
In the Introduction, add a sentence explicitly discussing limitations of prior studies (e.g., small sample sizes, lack of randomized data) to strengthen the scientific premise.
Both reviewers flagged that limitations of prior research are not explicitly addressed, which is a minor reporting gap.
2.
MEDIUMreporting
In the Methods, clarify how outliers and missing data (especially for PROs and secondary endpoints) were handled beyond defining ITT and safety populations.
Reviewer 1 rated outlier handling as inadequate; explicit description would improve methodological transparency.
3.
MEDIUMreporting
In the Methods, add a statement about the absence of blinding as a limitation, even though it is discussed in the Discussion.
Reviewer 2 suggested this to improve completeness of the Methods section.
4.
MEDIUMreporting
In the Methods, provide more detail on the randomization implementation (e.g., central randomization system).
Reviewer 2 noted that the randomization method is described but implementation details are sparse.
5.
MEDIUMreporting
In the Results, report the number of patients with PD-L1 unknown status in the baseline table, not just percentages.
Reviewer 2 suggested this to improve clarity of the baseline characteristics.
6.
MEDIUMreporting
In the Discussion, add a statement about the generalizability of the results to other populations (e.g., non-White, female).
Reviewer 2 suggested this to address potential limitations in external validity.
7.
MEDIUMdata code
Provide the full protocol and statistical analysis plan as supplementary material, with a direct link.
Reviewer 2 noted that the protocol is mentioned but not linked; making it accessible would enhance transparency.
8.
LOWcopyedit
In the Abstract, add 'the' before 'standard of care' for grammatical correctness.
Copyedit flagged a minor grammatical issue.
9.
LOWcopyedit
In the Results, ensure consistent use of semicolons and commas in lists (e.g., demographic data).
Copyedit flagged a punctuation inconsistency.
10.
LOWcopyedit
In the Abstract, change 'one-sided P = 0.0095' to 'P = 0.0095 (one-sided)' for consistency with other p-value reporting.
Copyedit flagged a style inconsistency.
11.
LOWcopyedit
In the Results, add 'respectively' after the list of TRAE percentages for clarity.
Copyedit flagged a clarity issue.

Full text (55,664 chars)Analyzed: Aug 15, 2026